Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected ...

Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder and Chief Scientific Officer, Dr. Victor ...

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

Does Carver leave Chicago Fire for good? Discover why Jake Lockett exits after season 13, what happens to Carver, and if he ...

The worldwide hyperphosphatemia industry is anticipated to reach a valuation of around USD 12.66 billion in 2023 and grow at a compound annual growth rate (CAGR) of more than 4.8% until 2033. By 2033, ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a milestone in the nation's fast-growing biotechnology realm ... market strategies ...

CAMBRIDGE, MA, USA I April 30, 2025 I Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has ...

Imagine if agricultural and food byproducts could be transformed into an effective and holistic feed for livestock while also ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...